1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A series of novel thiazolidin-4-ones bearing a lipophilic adamantyl substituent at position 2 or 3 were synthesized. A majority of them showed a modest anti-HIV-1 activity, whereas 2-adamantan-1-yl-3-(4,6-dimethylpyrimidin-2-yl)-thiazolidin-4-one ( 8) was endowed with a remarkable antiviral potency (EC 50 = 0.67 μM). The new series of compounds ( 2229) with an adamantyl moiety at the 3-position of the thiazolidinone ring showed good to modest anti-HIV-1 activity (EC 50 = 1.0–11 μM) but also pronounced cytostatic activity. For example 24, 26 and 29 showed an EC 50 of 1.0–2.0 μM, while the 50% effective concentrations for 23 and 28 were 7.8 and 11.0 μM, respectively. X-ray studies and quantum chemical calculations revealed that the anti-HIV activity of the compounds strongly depends on their dipole moments and conformation of the thiazolidinones.

          Graphical abstract

          Related collections

          Author and article information

          Contributors
          Journal
          Eur J Med Chem
          Eur J Med Chem
          European Journal of Medicinal Chemistry
          Elsevier Masson SAS.
          0223-5234
          1768-3254
          10 March 2008
          January 2009
          10 March 2008
          : 44
          : 1
          : 303-311
          Affiliations
          [a ]Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
          [b ]Warsaw University of Technology, Department of Chemistry, ul. Koszykowa 75, 00-662 Warsaw, Poland
          [c ]Institute of Atomic Energy, 05-400 Otwock-Świerk, Poland
          [d ]National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland
          [e ]Warsaw University of Life Sciences, Institute of Chemistry, ul. Nowoursynowska 159c, 02-787 Warsaw, Poland
          [f ]Military University of Technology, ul. Kaliskiego 2, 00-908 Warsaw, Poland
          Author notes
          []Corresponding author. Warsaw University of Life Sciences, Institute of Chemistry, ul. Nowoursynowska 159c, 02-787 Warsaw, Poland. andrzej_orzeszko@ 123456sggw.pl
          Article
          S0223-5234(08)00111-6
          10.1016/j.ejmech.2008.02.039
          7127420
          18420310
          90bfa087-8f5e-4169-a362-b4282b651934
          Copyright © 2008 Elsevier Masson SAS. All rights reserved.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 30 November 2007
          : 25 February 2008
          : 26 February 2008
          Categories
          Article

          Pharmacology & Pharmaceutical medicine
          thiazolidin-4-ones,adamantane derivatives,anti-hiv activity,nnrtis

          Comments

          Comment on this article